Structured Review

AK Scientific canertinib
Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , <t>Canertinib</t> (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).
Canertinib, supplied by AK Scientific, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/canertinib/product/AK Scientific
Average 91 stars, based on 1 article reviews
Price from $9.99 to $1999.99
canertinib - by Bioz Stars, 2020-09
91/100 stars

Images

1) Product Images from "Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method"

Article Title: Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method

Journal: Oncotarget

doi: 10.18632/oncotarget.21669

Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , Canertinib (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).
Figure Legend Snippet: Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , Canertinib (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).

Techniques Used: Staining, Multiple Displacement Amplification, Standard Deviation

Related Articles

Concentration Assay:

Article Title: Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method
Article Snippet: .. Compounds Mecamylamine (Sigma Aldrich), Canertinib (AK Scientific, Union City, CA), Bortezomib (AK Scientific), Tretinoin (AK Scientific), and AMG900 (Selleckchem, Houston, TX) were resuspended in dimethyl sulfoxide (DMSO – Canertinib, Bortezomib, Tretinoin, AMG900) or 200 proof ethanol (EtOH – Mecamylamine) at a concentration of 10 mM, stored at -20°C, and used at the indicated concentrations. .. Cell proliferation assays Cells were seeded into 96-well plastic tissue culture dishes at 2,000 (MCF10A and HCC1806), 5,000 (MDA-MB-453 and HCC1937), or 7,500 (BT549) cells per well on day 0.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    AK Scientific canertinib
    Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , <t>Canertinib</t> (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).
    Canertinib, supplied by AK Scientific, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/canertinib/product/AK Scientific
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    canertinib - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , Canertinib (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).

    Journal: Oncotarget

    Article Title: Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method

    doi: 10.18632/oncotarget.21669

    Figure Lengend Snippet: Validation of selected GenEx-TNBC predictions in TNBC cell lines of multiple molecular subtypes Crystal violet staining of HCC1937 (BL1), BT549 (ML), and MDA-MB-453 (LAR) cells grown in the presence of the indicated concentrations of Mecamylamine (A) , Canertinib (B) , Bortezomib (C) , and Tretinoin (D) for seven (7) days. Data for each cell line were normalized to the appropriate solvent control (ethanol for Mecamylamine, DMSO for all others). Data were analyzed by two-way ANOVA with Tukey post hoc multiple comparisons test (asterisks indicate per-dose comparisons) and are presented as the mean +/− standard deviation (S.D.) for a single experiment performed with 6 technical replicates that is representative of at least two independent experiments (biological replicates).

    Article Snippet: Compounds Mecamylamine (Sigma Aldrich), Canertinib (AK Scientific, Union City, CA), Bortezomib (AK Scientific), Tretinoin (AK Scientific), and AMG900 (Selleckchem, Houston, TX) were resuspended in dimethyl sulfoxide (DMSO – Canertinib, Bortezomib, Tretinoin, AMG900) or 200 proof ethanol (EtOH – Mecamylamine) at a concentration of 10 mM, stored at -20°C, and used at the indicated concentrations.

    Techniques: Staining, Multiple Displacement Amplification, Standard Deviation